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of the tumor cell. If the cell of origin has been through somatic hypermutation, and antigen selection, before neo-ULTIPLE MYELOMA is a malignant tumor involving plasma cells. Neoplastic cells are found in the bone marrow (BM), and typically secrete a monoclonal Ig plastic transformation, this experience should be reflected in the V-gene sequences. For V H regions of antibody molecules, of IgG or IgA isotype. Although the major identifiable tumor population consists of plasma cells, there has been a great it is known that recognition of antigen can involve several sites, with CDR3 having a major influence. 15 However, redeal of debate concerning the nature of the malignant cell, with some early indications that this may be a less mature placement mutations in CDR1 and CDR2 have a significant role in affinity maturation. 11, 16 For B-cell tumors, where the B cell capable of ''feeding'' the plasma cell compartment.
1,2
The advent of genetic technology aimed at Ig genes has putative antigen is generally unknown, it is difficult to estimate involvement of CDR3 in recognition. In contrast, the allowed a more incisive investigation of the characteristics of myeloma clones. In fact, there have now been reports of possible clustering of replacement mutations in CDR1 and CDR2 which could be involved in affinity maturation can a total of more than 50 sequences of V H genes used by tumor cells from patients' BM biopsies, and these have revealed be analyzed. Rules to assess the significance of apparent clustering of replacement mutations compared with silent common features. [3] [4] [5] One conclusion is that usage of V H genes from the availmutations have been developed. 17 When these rules were applied to the large panel of V H sequences from myeloma able repertoire appears to reflect no striking bias, with predominance of the large V H 3 family in line with serological cells, only a minority of cases (10 of 52) showed statistically significant clustering in CDRs. 5 However, the antigen-bindanalysis of myeloma proteins. 6 However, at the level of individual V H genes there may be some asymmetry in usage.
ing site is known to involve both V H and V L , 18 and we have investigated V L sequences from a group of 15 patients both For example, one gene, V , commonly used by normal B cells, and mandatory for encoding IgM autoanti-red blood to extend our knowledge of Vk and Vl gene usage in myeloma, and to assess the role of V L in the selection of the cell antibodies of I/i specificity in patients with cold agglutinin disease, 7 has so far not been found to be used by tumor cell of origin by antigen. cells in myeloma. 5, 8 In all cases of myeloma, the V H genes
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have been found to be somatically hypermutated. [3] [4] [5] A further common feature is the lack of intraclonal variation in sePatients and cell preparation. Heparinized BM aspirates from unselected patients with multiple myeloma at different stages of quence, a finding that contrasts with the heterogeneity found in B-cell tumors of the germinal center. 9, 10 This leads to the conclusion that the final tumorigenic event in myeloma has Tables 3 and 4 for Vk and Vl, respectively.
The profile of Vk genes used by the 9 k-positive tumors ried out by the method of Chang and Casali. 17 In this method, these cases indicated a significant clustering in CDRs (Table  6 ). Comparison of patterns in V H with those in V L (Table 6 ) each V L or V H gene sequence is assessed codon by codon for significance of deviation from germline sequence. A showed that clustering in CDRs of V H was not paralleled by clustering in CDRs of V L . In addition, the clustering in V L modification of the binomial distribution model is then used to calculate whether the probability (P in Tables 5 and 6) 3, 6, 8, 14 , and 15), tumor-derived V H gene sequences were a V H sequence from a tumor cell to the germline gene of origin with confidence. Although some nucleotide changes known. 4, 29 V H sequences from the remaining 9 patients were obtained as described 4 and deduced amino acid sequences are may reflect polymorphic variation, particularly for certain V H 3 genes, 31 it can be assumed that the majority of deviations shown in Fig 4. Nucleotide sequences have been submitted to EMBL/GenBank database (accession numbers: Z70256-257; from germline sequence in V H genes of a B cell represent somatic mutations. 21 In some cases this has been proved by Z75556-5557; X98899-99003). Although the closest germline gene has been obtained from the database, rather than comparing the tumor-derived sequence with the germline counterpart in the patient. 4, 5 Accumulation of such mutations from the patients' DNA, it appears that in general polymorphism in V H is not sufficient to require this approach. 21 In indicate that the cell of origin has been exposed to the hypermutation mechanism in the germinal center. 11, 18, 32 Heterogefact, where we 4 and others 5 have analyzed the patients' germline V H genes, the sequence has been found in the majority neity of mutations within the tumor clone indicates that the tumor cell is still under the influence of the mutation mechaof cases to correspond exactly to that obtained from the database. However, in 1 of 9 cases of myeloma, a 2-bp nism, subsequent to neoplastic transformation. 9, 10 Finally, concentration of replacement mutations in CDRs can suggest difference from the published sequence of a VII-5 germline gene was found also in the patient's germline sequence, a role for antigen in selection of the B cell.
17,33
In the case of multiple myeloma, V H gene analyses from indicating that this was probably caused by a polymorphism.
5
The distribution of somatic mutations in V H of 6 of 15 of several laboratories have shown that the malignant cell has undergone extensive somatic hypermutation. [3] [4] [5] There is furphase. 34 These findings strongly suggest that the malignant cell has exited from the germinal center, and is no longer ther wide agreement that there is no intraclonal heterogeneity among the tumor cell population, [3] [4] [5] and there is evidence susceptible to the mutation mechanism. 4, 5 The germline repertoire of V L genes has also been that the V H sequence is stable from diagnosis through plateau mapped, 27, 35, 36 but there have been fewer studies of usage in B-cell tumors. In myeloma, using DNA as a source, 7 Vk . 5,14 This leaves open the cloned PCR product supports the derivation from tumor cells, which can be a problem otherwise. We have analyzed the question of the clonal history of the tumor cells in the remaining 79% of the cases. Because V L sequence is also the pattern of both Vk and Vl sequences. These confirm the high level of somatic hypermutation, with the level of 5.8% known to be involved in recognition of antigen, 18 deductions from V-gene sequences that relate to a role for antigen in mutation for V L being comparable with that of 8.2% for V H .
There is also a lack of intraclonal heterogeneity in V L of all selection should be strengthened by including analysis of V L . patients, again confirming findings in V H , and supporting the concept that the final event in malignant transformation
In this study, significant clustering of mutations in CDRs of V L was seen in 4 of 15 sequences. In contrast, a prelimihas occurred at a postfollicular stage. 3, 4, 14 In contrast, the V H genes in the benign counterpart of myeloma (monoclonal nary report of a study of Vk sequences in 9 cases of myeloma has indicated that clustering of replacement mutations in gammopathy of undetermined significance or MGUS), showed intraclonal heterogeneity in 3 of 7 cases. 29 This could CDRs occurred in all cases, but more details of the analysis are required. 39 In our cases, comparison with V H sequence indicate that the clonal plasma cell in MGUS is less mature, and may have undergone some, but not all the events leading in the same cell showed that clustering was in either V H or V L , but not both. This suggests that a role for antigen might to malignant behavior.
29
If the final neoplastic event is late in maturation of the B be more common than estimated from V H alone, reaching 67% in our study. There have been insufficient studies of cell, it might be expected that the myeloma precursor cell will have been subjected to the same processes of developnormal human B cells to know if this is a typical finding. Investigation of the classical murine response to the hapten ment as a normal B cell. Even if there is an IgM / clonal precursor, which has undergone some neoplastic event, the phenyl oxazolone has shown that affinity maturation is accompanied by somatic mutations in the CDRs of both V H few cases available for analysis have indicated that it has a homogeneous V H gene sequence identical to the isotypeand Vk. 40 This is likely to be the case in human antibodies, and might suggest that a role for antigen is more common switched plasma cell. 12, 13, 38 This would argue that neoplastic transformation in myeloma begins in a mature B cell immethan estimated from V H alone. For myeloma, the findings support the idea that the cell of origin has undergone the diately before isotype-switch. Because a B cell would have reached this point following antigen selection, the imprint process of conventional antigen selection. However, there remains a minority of sequences which appear to have no of this procedure should remain as a clustering of mutations in CDRs of V-gene sequences. 11, 17, 33 In fact, analysis of the clustering in either V-region. Blood (print ISSN 0006-4971, online ISSN 1528-0020) , is published weekly by the American Society of
